Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Henlius Biotech Inc.

http://www.henlius.com/en/Index.html

Latest From Shanghai Henlius Biotech Inc.

Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.

Deals Business Strategies

Aurobindo Is Company Of The Year At GGB Awards

Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

Generic Drugs Biosimilars

Henlius Biotech IPO Raises Below-Target $410m

Shares of China’s Shanghai Henlius Biotech will debut on the Hong Kong stock exchange later this week after the company collected $410m in an IPO that was priced at the bottom end of the targeted range.

Strategy Biosimilars

Asia Deal Watch: Daiichi Sankyo Obtains Brazilian Rights To Mitsubishi Tanabe’s ALS Drug

Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Shanghai Henlius Biotech Inc.
  • Senior Management
  • Scott Liu, Pres. & CEO
    Zidong Zhang, CFO
    Wei-Dong Jiang, CSO
    Alvin Luk, SVP, CMO
    Junli Zhang, SVP, COO
    Ping Cao, VP, Bus. Dev.
  • Contact Info
  • Shanghai Henlius Biotech Inc.
    Phone: 21 33395800
    9/F, Innov Tower, Zone A
    1801 Hongmei Rd
    Shanghai, 200233
    China
UsernamePublicRestriction

Register